{"prompt": "['Appendix 1', 'Schedule of Activities (cont.)', 'Safety', 'Early', 'Follow-', 'Termination /', 'Screening', 'Treatment', 'Study', 'up', 'Visit', 'Completion', '[a]', 'Wk -4 to', '15 m', '21 m', 'Unscheduled', 'Visits', 'Wk 1', 'Wk 2', 'Wk 3', 'Wk 5', '3 m', '6 m', '9 m', '12 m', '18 m', 'Wk 0', '[b]', '[b]', 'visit', '2 years', 'Time Window, days', '+ 2', '+ 2', '+ 2', '+ 7', '+ 7', '+ 7', '+ 14', '+ 14', '+ 30', '+ 30', '+ 30', 'ePRO bleed /', 'medication recording', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '[m]', 'Surgical events [n]', 'X', 'x', 'X', 'x', 'X', 'X', 'X', 'x', 'X', 'X', 'x', 'x', 'x', 'x', 'x', 'Adverse events [o]', 'x', 'X', 'X', 'X', 'X', 'X', 'Management of', 'X', 'X', 'X', 'emicizumab [p]', 'HRQoL [q]', 'X', 'Health status', 'X', '(EQ-5D-5L) [q]', 'Treatment', 'preference', 'questionnaire', '(EmiPref) [r]', 'PK assessment [s,t]', 'X', 'X', 'Safety biomarkers', 'X', 'x', 'assessment [s,u]', 'Safety coagulation', 'system biomarkers', 'X', 'assessment [s,v]', 'PD biomarkers', 'X', 'X', 'X', 'X', 'X', 'assessment [s,w]', 'Emicizumab - F. Hoffmann-La Roche Ltd', '159 / Protocol MO39129, Version 3']['Appendix 1', 'Schedule of Activities (cont.)', 'Safety', 'Early', 'Follow-', 'Termination /', 'Screening', 'Treatment', 'Study', 'up', 'Visit', 'Completion', '[a]', 'Wk -4 to', '15 m', '21 m', 'Unscheduled', 'Visits', 'Wk 1', 'Wk 2', 'Wk 3', 'Wk 5', '3 m', '6 m', '9 m', '12 m', '18 m', 'Wk 0', '[b]', '[b]', 'visit', '2 years', 'Time Window, days', '+2', '+ 2', '+ 2', '+7', '+ 7', '+ 7', '14', '+ 14', '+ 30', '+ 30', '+ 30', 'Bone and joint', 'biomarker', 'X', 'X', 'X', 'X', 'assessment (fasting)', '[s,x]', 'Additional laboratory', 'assessments [y]', 'For breakthrough bleeds treated with bypassing agents', 'Emicizumab', 'administration', 'Weekly subcutaneous injection', 'd=day; eCRF=electronic Case Report Form; EQ-5D-5L=EuroQol Five-Dimension-Five Levels Questionnaire; FVIII=Factor VIII; Haem-A-QoL=Hemophilia', 'Adult Quality of Life Questionnaire; Haemo-QoL-SF=Hemophilia Quality of Life Short Form; HIV=human immunodeficiency virus; HRQoL=Health-Related', 'Quality of Life; m=months (based on calendar months); PD=pharmacodynamic; PK=pharmacokinetic; Wk=week', 'Notes: the maximum allowable time between Screening and enrollment is 4 weeks; if the elapsed time between Screening and enrollment', 'is', 'more', 'than', '4', 'weeks, Screening must be repeated.', 'Except for the bleed/medication records, all other patient data will be collected during clinic visits.', \"b. Patients who discontinue emicizumab prior to the completion of the 2-year treatment period will undergo a Safety Follow-up Visit 24 weeks after the patient's last\", 'emicizumab dose or at 2 years after emicizumab treatment start, whichever occurs first.', 'c.', \"Optional visits, as per the investigator's discretion.\", 'd. Written informed consent must be obtained before any study-specific screening tests or evaluations are performed. For adolescents (i.e., patients who are', '12-17 years of age), an Informed Assent Form will be completed instead. Parents or caregivers of adolescents will also complete an Informed Consent Form. The', 'enrollment form will be completed after informed consent and/or assent is obtained. All screening evaluations must be completed and reviewed to confirm that', 'patients meet all eligibility criteria before enrollment.', 'e.', 'Medical history and demographics data will be collected from patient medical records and documented in the eCRF. Medical history includes hemophilia-', 'related history, clinically significant diseases, procedures (including prior surgeries), use of alcohol and drugs of abuse within the past year, and medication allergies. In', 'particular, sites should record whether the patient has any history of prior ITI, anaphylaxis, or known thrombophilia. It should also include all medication taken in the', 'Emicizumab - F. Hoffmann-La Roche Ltd', '160 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}